COVID-19幸存者肝素酶水平升高——血管与肺恢复的标志?
该前瞻性延长队列研究纳入47例ICU的COVID-19患者,每日用酶联免疫吸附法测定血浆HPSE与肝素结合蛋白(HBP),比较幸存者(n=35)与死亡者(n=12)及健康对照。幸存者与死亡者的HPSE、HBP均显著高于健康对照;幸存者HPSE显著高于死亡者(P<0.001),而HBP显著低于死亡者(P<0.001)。接受肝素治疗时HPSE显著低于接受低分子肝素(LMWH)时(P=2.22e-16),HBP显著高于LMWH时(P=0.00013)。作者认为HPSE不适合作为COVID-19病情严重度标志,但可能作为患者康复的标志。
要点
- COVID-19幸存者血浆HPSE显著高于死亡者(P<0.001),作者认为HPSE可能作为康复标志而非病情严重度标志。
- 幸存者血浆HBP显著低于死亡者(P<0.001),与HPSE方向相反。
- 接受肝素治疗时HPSE显著低于接受LMWH时(P=2.22e-16),HBP显著高于LMWH时(P=0.00013)。
- 幸存者与死亡者HPSE、HBP均显著高于健康对照。
- 所有患者均接受肝素或LMWH抗凝,目标活化部分凝血活酶时间≥60秒或抗Xa水平>0.8 IU/mL。
适用人群与场景
- ICU收治的COVID-19患者47例,其中幸存者35例、死亡者12例,自入ICU至出院或死亡每日采血。
- 接受体外膜氧合或去甲肾上腺素>0.1 μg/kg/min者用肝素,其余用依诺肝素。
处置流程与药物剂量
- 所有患者接受肝素或LMWH抗凝,目标活化部分凝血活酶时间≥60秒或抗Xa水平>0.8 IU/mL,依诺肝素剂量根据临床状态决定。
- 接受体外膜氧合或去甲肾上腺素>0.1 μg/kg/min的患者使用肝素,其余患者使用依诺肝素。
研究设计与关键结果
- 前瞻性延长队列研究,纳入47例ICU的COVID-19患者(幸存者35例、死亡者12例),每日用酶联免疫吸附法测定血浆HPSE与HBP。
- 幸存者与死亡者血浆HPSE和HBP均显著高于健康对照。
- 幸存者血浆HPSE显著高于死亡者(P<0.001);幸存者血浆HBP显著低于死亡者(P<0.001)。
- 接受肝素治疗时血浆HPSE显著低于接受LMWH时(P=2.22e-16),HBP显著高于LMWH时(P=0.00013)。
证据类型、等级与局限
- 证据类型:前瞻性延长队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,HPSE不适合作为COVID-19病情严重度标志,但可能作为患者康复的标志。
- 作者指出,接受治疗性肝素的患者血浆HPSE显著低于接受治疗性LMWH的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Severe progression of coronavirus disease 2019 (COVID-19) causes respiratory failure and critical illness. Recently, COVID-19 has been associated with heparanase (HPSE)-induced endothelial barrier dysfunction and inflammation, so called endothelitis, and therapeutic treatment with heparin or low-molecular-weight heparin (LMWH) targeting HPSE has been postulated. Because, up to this date, clinicians are unable to measure the severity of endothelitis, which can lead to multiorgan failure and concomitant death, we investigated plasma levels of HPSE and heparin-binding protein (HBP) in COVID-19 intensive care patients to render a possible link between endothelitis and these plasma parameters. Therefore, a prospective prolonged cohort study was conducted, including 47 COVID-19 patients from the intensive care unit. Plasma levels of HPSE, and HBP were measured daily by enzyme-linked immunosorbent assay in survivors (n = 35) and nonsurvivors (n = 12) of COVID-19 from admission until discharge or death. All patients were either treated with heparin or LMWH, aiming for an activated partial thromboplastin time of ≥60 seconds or an anti-Xa level of >0.8 IU/mL using enoxaparin, depending on the clinical status of the patient (patients with extracorporeal membrane oxygenation or >0.1 μg/kg/min noradrenaline received heparin, all others enoxaparin). Results: We found significantly higher plasma levels of HPSE and HBP in survivors and nonsurvivors of COVID-19, compared with healthy controls. Still, interestingly, plasma HPSE levels were significantly higher ( P < 0.001) in survivors compared with nonsurvivors of COVID-19. In contrast, plasma HBP levels were significantly reduced ( P < 0.001) in survivors compared with nonsurvivors of COVID-19. Furthermore, when patients received heparin, they had significantly lower HPSE ( P = 2.22 e - 16) and significantly higher HBP ( P = 0.00013) plasma levels as when they received LMWH. Conclusion: Our results demonstrated that patients, who recover from COVID-19-induced vascular and pulmonary damage and were discharged from the intensive care unit, have significantly higher plasma HPSE level than patients who succumb to COVID-19. Therefore, HPSE is not suitable as marker for disease severity in COVID-19 but maybe as marker for patient's recovery. In addition, patients receiving therapeutic heparin treatment displayed significantly lower heparanse plasma level than upon therapeutic treatment with LMWH.
参考来源
- Neb H, Talbot SR, Ruskowski K, et al. HIGH HEPARANASE LEVEL IN SURVIVORS OF COVID-19 - INDICATOR OF VASCULAR AND PULMONARY RECOVERY? Shock. 2022. PMID: 36548643. doi:10.1097/SHK.0000000000002021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。